Search
Teva’s shares have underperformed competitors’ this year amid speculation the multiple sclerosis medicine Copaxone may lose market share to new treatments such as Novartis AG’s Gilenya.

Photographer: Akos Stiller/Bloomberg

Teva’s shares have underperformed competitors’ this year amid speculation the multiple sclerosis medicine Copaxone may lose market share to new treatments such as Novartis AG’s Gilenya.
November 30, 2012
Article
Teva Sees 2013 Sales, Profit Below Analyst Estimates
« Back to Home